Posted on 03/01/2017 12:43:17 AM PST by Jyotishi
Caption -- New research suggests people with chronic pain would rather use cannabis over their recommended medicine.
Chronic pain sufferers and those taking mental health meds would rather turn to cannabis instead of their prescribed opioid medication, according to a new study.
"This study is one of the first to track medical cannabis use under the new system of licensed producers, meaning that all participants had physician authorization to access cannabis in addition to their prescription medicines," says UBC Assoc. Prof. Zach Walsh, co-author of the study.
The study tracked more than 250 patients with prescribed medical cannabis--people treated for conditions such as chronic pain, mental health and gastrointestinal issues. Overall, 63 per cent of respondents reported using cannabis instead of their prescription drugs, which included opioids (to treat pain), benzodiazepines (sedatives) and anti-depressants.
Study lead Philippe Lucas is vice-president of Patient Research and Access at Tilray, a federally authorized medical cannabis production and research company, and a doctoral student at the University of Victoria Centre for Addictions Research of BC. Lucas suggests the main reasons for the switch to cannabis from prescribed meds is due to reduced side effects, better symptom management and a feeling that cannabis is safer than prescription drugs.
Walsh goes on to suggest cannabis may have an important role to play in addressing the problematic use of pharmaceutical medications such as opioids.
Caption -- UBC Assoc. Prof. Zach Walsh, co-author of the study.
In 2001, Canada became one of the first nations to develop a program to allow access to cannabis for medical purposes. As of August 2016 more than 30 federally authorized licensed producers of cannabis provided product to more than 65,000 patients.
"Further research into how well cannabis works compared to the accepted front-line treatments is warranted," says Walsh. "Additionally, long-term research into the potential impact of the cannabis substitution on the quality of patient's lives is ongoing."
The study, published in International Journal of Drug Policy, was funded by Tilray.
http://www.sciencedirect.com/science/article/pii/S0955395917300130
“The poor solubility of Marinol in aqueous solutions and its high first-pass metabolism in the liver account for its poor bioavailability; only 10-20% of an oral dose reaches the systemic circulation. The onset of action is slow; peak plasma concentrations are not attained until two to four hours after dosing. In contrast, inhaled marijuana is rapidly absorbed. In a study comparing THC administered orally, by inhalation, and intravenously, plasma concentration peaked almost instantaneously after both inhalation and intravenous administration; most participants’ peak plasma concentrations after oral administration occurred at 60 or 90 minutes. Variation in individual responses is highest for oral THC and bioavailability is lowest.” - https://www.nap.edu/read/6376/chapter/7#203
Weak resistance level.
patients can receive a drip medication for anti nausea during chemo treatments. my relative does. no nausea since 1st episode. They have had about 10 more chemo sessions over the course of a few months no problem ( except fatigue the rest of day and some times the following day).
People need to get better educated oncologists who actually work with patients, not just give “ the standard of care” baloney and leave the patient with unnecessary symptoms and discomfort.
Disclaimer: Opinions posted on Free Republic are those of the individual posters and do not necessarily represent the opinion of Free Republic or its management. All materials posted herein are protected by copyright law and the exemption for fair use of copyrighted works.